Federico Viganego
Overview
Explore the profile of Federico Viganego including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee D, Hawk F, Seok K, Gliksman M, Emole J, Rhea I, et al.
Heart
. 2021 Jul;
108(6):445-450.
PMID: 34210750
Background: Ibrutinib is a tyrosine kinase inhibitor most commonly associated with atrial fibrillation. However, additional cardiotoxicities have been identified, including accelerated hypertension. The incidence and risk factors of new or...
2.
Viganego F, Um E, Ruffin J, Fradley M, Prida X, Friebel R
Circ Cardiovasc Qual Outcomes
. 2021 Feb;
14(3):e007110.
PMID: 33622052
Background Global budget payments (GBP) are considered effective in containing health care expenditures; however, information on their impact on quality of cardiovascular care is limited. We aimed to evaluate the...
3.
Fradley M, Welter-Frost A, Gliksman M, Emole J, Viganego F, Lee D, et al.
Cancer Control
. 2020 Jun;
27(1):1073274820931808.
PMID: 32496158
Although ibrutinib-associated atrial and ventricular arrhythmias have been well described, there is little information about ibrutinib's effects on other electrocardiographic parameters, particularly the QT interval. Using our database of 137...
4.
Fradley M, Gliksman M, Emole J, Viganego F, Rhea I, Welter-Frost A, et al.
Am J Cardiol
. 2019 Jun;
124(4):539-544.
PMID: 31208701
There is increasing evidence that rates of atrial arrhythmias (AA), specifically atrial fibrillation and flutter are elevated in patients treated with the tyrosine kinase inhibitor, ibrutinib; however, the exact risk...
5.
Fradley M, Viganego F, Kip K, Martin A, Patel A, Ismail-Khan R, et al.
Open Heart
. 2018 Jan;
4(2):e000701.
PMID: 29344369
Objectives: There is little information about arrhythmia burden in cancer survivors with chemotherapy-induced cardiomyopathy (CIC). We hypothesise that the rates and risk of arrhythmias will be similar in CIC when...
6.
Fradley M, Brown A, Shields B, Viganego F, Damrongwatanasuk R, Patel A, et al.
Oncol Rev
. 2017 Aug;
11(2):340.
PMID: 28781723
Cardio-oncology is a multidisciplinary field focusing on the management and prevention of cardiovascular complications in cancer patients and survivors. While the initial focus of this specialty was on heart failure...
7.
Viganego F, Singh R, Fradley M
Curr Cardiol Rep
. 2016 Apr;
18(6):52.
PMID: 27108362
Enhanced understanding of cancer biology has significantly increased treatment options and dramatically improved outcomes for patients with malignancies. Despite these advances, many therapies have cardiovascular toxicities which can affect morbidity...
8.
Brinda B, Viganego F, Vo T, Dolan D, Fradley M
Curr Treat Options Cardiovasc Med
. 2016 Mar;
18(5):33.
PMID: 26932588
Abnormal intracellular signaling has been implicated in the development of many different types of cancer. Therapies targeting these abnormal pathways have revolutionized the treatment of many malignancies leading to significantly...
9.
Maluenda G, Bustos F, Viganego F, Ben-Dor I, Hanna N, Torguson R, et al.
Cardiovasc Revasc Med
. 2012 Jul;
13(4):215-8.
PMID: 22818532
Background: Several patients undergoing permanent pacemaker (PPM) implantation/upgrade present with difficult access due to sub- or total central vein occlusion. Our institution has used the endovascular approach to recanalize central...
10.
Viganego F, ODonoghue S, Eldadah Z, Shah M, Rastogi M, Mazel J, et al.
Am J Cardiol
. 2012 Feb;
109(10):1466-71.
PMID: 22356796
Cardiac device infections (CDIs) represent a serious complication after the implantation of pacemakers and defibrillators. In addition to antimicrobials, complete hardware removal, mostly with percutaneous lead extraction (PLE), is necessary...